Ocular Toxicity of Tyrosine Kinase Inhibitors
- 1 March 2016
- journal article
- review article
- Published by Oncology Nursing Society (ONS) in Oncology Nursing Forum
- Vol. 43 (2) , 235-243
Abstract
To review common tyrosine kinase inhibitors, as well as their ocular side effects and management. . A comprehensive literature search was conducted using CINAHL®, PubMed, and Cochrane databases for articles published since 2004 with the following search terms. Tyrosine kinase inhibitors can cause significant eye toxicity. . Given the prevalence of new tyrosine kinase inhibitor therapies and the complexity of possible pathogenesis of ocular pathology, oncology nurses can appreciate the occurrence of ocular toxicities and the role of nursing in the management of these problems. . Knowledge of the risk factors and etiology of ocular toxicity of targeted cancer therapies can guide nursing assessment, enhance patient education, and improve care management. Including a review of eye symptoms and vision issues in nursing assessment can enhance early detection and treatment of ocular toxicity.Keywords
This publication has 29 references indexed in Scilit:
- Ocular side effects of biological agents in oncology: what should the clinician be aware of?OncoTargets and Therapy, 2013
- Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disordersClinical Interventions in Aging, 2013
- Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year reviewSupportive Care in Cancer, 2012
- Genomics and the EyeNew England Journal of Medicine, 2011
- Retinal-Vein OcclusionNew England Journal of Medicine, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- PD0325901, a Mitogen-Activated Protein Kinase Kinase Inhibitor, Produces Ocular Toxicity in a Rabbit Animal Model of Retinal Vein OcclusionJournal of Ocular Pharmacology and Therapeutics, 2009
- Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patientsCurrent Opinion in Ophthalmology, 2009
- Autologous Serum Eye Drops for the Treatment of Dry Eye DiseasesCornea, 2008
- Ocular Side-Effects Associated with Imatinib Mesylate (Gleevec ® )Journal of Ocular Pharmacology and Therapeutics, 2003